Rilzabrutinib and Bruton tyrosine kinase inhibition for the treatment of persistent or chronic immune thrombocytopenia

The approval of rilzabrutinib represents an important advancement in the treatment of ITP and adds to the therapeutic armamentarium for this patient population. While rilzabrutinib has demonstrated efficacy compared to placebo in previously treated ITP patients, there is a lack of direct comparisons with other treatment options. The safety profile of rilzabrutinib differs from other BTK inhibitors approved for B-cell malignancies. Rilzabrutinib is subject to numerous drug-drug interactions, and careful selection of this agent and review of concomitant medications will be important to ensure its safe and effective use.